WC
BEAM icon

Wexford Capital’s Beam Therapeutics BEAM Stock Holding History

Wexford Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,453
Closed -$246K – 409
2025
Q2 		$246K Buy
+14,453
New +$252K 0.07% 162
2022
Q1 		– Sell
-11,626
Closed -$926K – 157
2021
Q4 		$926K Buy
+11,626
New +$995K 0.04% 102

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wexford Capital's BEAM Position: Q3 2025 in Review

Wexford Capital sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 14,453 shares — an estimated $246K sold.

Wexford Capital first reported a position in BEAM in Q4 2021 and held it in 2 quarters. The position peaked at $926K in Q4 2021. 219 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

  • Wexford Capital reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wexford Capital sold 14,453 Beam Therapeutics shares in Q3 2025, an estimated $246K.
  • Wexford Capital first reported a position in Beam Therapeutics in Q4 2021 and held it in 2 quarters.
  • Wexford Capital's Beam Therapeutics position peaked at $926K in Q4 2021.
  • 219 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on Wexford Capital's 13F filing for Q3 2025, filed 14 Nov 2025.